Core Viewpoint - Travere Therapeutics (TVTX) shows potential for significant upside, with a mean price target of $27.20 indicating a 42.6% increase from the current price of $19.08 [1] Price Target Analysis - The mean estimate consists of 15 short-term price targets with a standard deviation of $8.33, indicating variability among analysts [2] - The lowest estimate is $18, suggesting a 5.7% decline, while the highest estimate predicts a 120.1% increase to $42 [2] - A low standard deviation indicates strong agreement among analysts regarding price movement direction [7] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about TVTX's earnings prospects, with a positive trend in earnings estimate revisions [9] - The Zacks Consensus Estimate for the current year has risen by 0.9% over the past month, with no negative revisions [10] - TVTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as they can mislead investors [3][5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]

Core Viewpoint - Travere Therapeutics, Inc. will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 8:15 a.m. PT, highlighting its commitment to addressing rare diseases [1] Group 1: Company Overview - Travere Therapeutics is a biopharmaceutical company focused on developing therapies for patients with rare diseases, emphasizing the urgent need for treatment options [2] - The company collaborates with the rare disease community to identify, develop, and deliver life-changing therapies, aiming to provide hope for patients and their families [2] Group 2: Event Details - Eric Dube, Ph.D., the president and CEO of Travere Therapeutics, will be the presenter at the upcoming healthcare conference [1] - A live webcast of the presentation will be available on the company's investor page, with a replay accessible for up to 30 days post-event [1]

Group 1 - Travere Therapeutics received full approval for its sparsentan 200/400 mg tablets, branded as Filspari, for the treatment of IgA nephropathy (IgAN) [1] - IgAN is a chronic kidney disease caused by the immune system producing abnormal antibodies [1] Group 2 - The article does not provide additional relevant content for further summarization.

Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Homocystinuria - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Homocystinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactiv ...

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be $125.0 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on November 12, 2024, subject to customary ...

or UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________ FORM 10-Q _________________________________ ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact na ...

Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 IR@travere.com mediarelations@travere.com Travere Therapeutics Reports Third Quarter 2024 Financial Results ® FILSPARI (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss potential sNDA submission for FILSPARI in FSGS sNDA requesting modification of liver monitoring for FILSPARI submitted to FDA Net product sal ...

Company Overview - Travere Therapeutics, Inc. (NASDAQ: TVTX) focuses on treatments for rare kidney and metabolic diseases [1] - The company's portfolio includes FDA-approved drugs such as Filspari (Sparsentan) for IgA Nephropathy (IgAN) and Thiola (Tiopronin) for cystinuria [1] Recent Developments - Filspari received full FDA approval in September 2024, which expanded its label and increased patient access [1]

SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU). The voluntary enrollment pause enables the Company to work to address necessary process improvements in manufacturing scale-up to support commercial scale manufacturing as well as full enrollment in the HARMONY Study. Patients currently enrolled in pegtibatinase studi ...

Travere Therapeutics (TVTX) shares rallied 5.9% in the last trading session to close at $14.27. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 55.3% gain over the past four weeks. The company markets Filspari (sparsentan), an oral non-immunosuppressive drug approved for treating IgA nephropathy (IgAN), a rare kidney disease. Filspari has seen strong market demand, generating $47 million in sales in the first ...